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ABSTRACT

A method of decreasing the expression of LIM kinase 1 in a
cancer cell comprising; providing an oligonucleotide consisting of the sequence of SEQ ID NO: 1; providing a cancer cell
comprising an mRNA encoding LIM kinase 1; and introducing the oligonucleotide into the cancer cell, wherein the oligonucleotide decreases the expression of LIM kinase 1 in the
cancer cell. The method also provides compositions of an
antisense RNA LIM kinase 1 that can be administered to an
individual for the purpose of inhibiting a protein kinase pathway and which further comprises methods for treating and
monitoring the proliferation and metastasis of cancer cells. A
kit may be used in the detection and treatment of cancer.
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METHODS AND COMPOSITIONS FOR
INHIBITING THE PROLIFERATION OF
CANCER CELLS

normal cellular function. The concentration of LIMKl has
previously been found at increased levels in some cancer
cells; for example, cancer cells that are highly aggressive and
capable of causing metastasis or the spread of tumors in mice.
Research has shown that a partial inhibition ofLIMK 1 synthesis using antisense RNA in these cells resulted in the
inhibition of cell growth and more specifically, regression of
the invasive property of these cells.
Efforts to identify compositions which inhibit the expression ofLIMK 1 and, which therefore, should be useful in the
treatment and prevention of cancer cell metastasis, has led to
the use of the "antisense" or non-encoding LIM Kinase 1,
which exhibits an ability to inhibit the expression of LIMK 1
in certain cancer cells.
Antisense RNA mediated gene therapy is a widely used
method of gene inactivation and is suitable for gene therapy
use. However, RNA mediated gene inactivation does not
work for all genes, and may not be used as a global method of
gene inactivation.

RELATED APPLICATIONS
This application is a divisional ofU.S. Ser. No. 12/706,218
filed Feb. 16, 2010 now issued as U.S. Pat. No. 8,415,315,
which is a continuation ofU.S. Ser. No. 10/840,737 filed May
6, 2004 now abandoned, which are incorporated herein in
their entirety.

10

BACKGROUND
The following is offered as background information only
and is not admitted to be prior art to the present invention.
Cancer cells are characterized by an ability to proliferate
indefinitely and to invade normal tissue cells surrounding a
cancerous tumor. In addition, many types of cancer cells can
metastasize throughout the body whereby the tumor may be
disseminated in the cancer patient's body.
The mechanism of cancer metastasis is presumed as follows: (1) cancer cells proliferate in a primary cancer colony;
(2) blood vessels are newly formed; (3) the malignant cancer
cells infiltrate and penetrate the newly formed blood vessels;
(4) the cancer cells circulate within the human body; (5) the
cancer cells reach a target organ; (6) the cancer cells extravasate from blood vessels; (7) the cancer cells proliferate in the
target organ; and (8) a metastatic focus is formed.
The cure rate of malignant cancer tumors has increased
with early diagnosis and with the progress of therapies, but
metastases of malignant tumors are often beyond current
therapies. Chemotherapies are used to arrest metastases following removal of tumors but often with unsatisfactory
results. It is therefore desirable to develop more effective
inhibitors against malignant tumor metastases.
Conventional methods for treating cancer have also
increased the survival and quality of life for cancer patients.
Such conventional methods include surgery, for example,
removal of the prostate gland (radical prostectomy), radiotherapy, and chemotherapy. In addition, bone marrow transplantation is becoming useful in treating patients with certain
types of cancers.
Combination therapies may be used in treating cancer and
are typically not addictive. In some cases, cross effects and
treatment load can result in a lower effectiveness for the
combinations, than either treatment alone.
Other treatments such as radiation, while useful for a wide
range of cancers, does not typically result in a complete cure.
Given the severity of many cancers and the mortality rate, a
drug may be thought of as successful ifit improves the quality
of life by delaying the growth of tumors, or if it prolongs life
without actually curing the condition. In many circumstances, an individual is treated with a specific composition or
with a combination of therapies that can eliminate from about
90 to about 95% of the malignant cells, but the remaining cells
can re-grow and metastasize, ultimately resulting in death.
LIM kinase 1 (LIMK 1) is one of the regulatory proteins
that modulate the actin cytoskeleton by inactivating an actinbinding protein, cofilin, through addition of a phosphate
group to cofilin. Actin cytoskeleton is maintained by the
constant severing and joining of small units of actin and any
deviation away from this normal dynamic may lead to abnormal behavior of a particular cell. LIMKl plays an important
role in maintaining cell architecture through actin cytoskeleton. As an important regulator of cell behavior, levels of
LIMKl need to be regulated in cells for the maintenance of
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Before explaining the disclosed embodiment of the present
invention in detail it is to be understood that the invention is
not limited in its application to the details of the particular
arrangement shown since the invention is capable of other
embodiments. Also, the terminology used herein is for the
purpose of description and not of limitation.
In one embodiment, the present invention provides, for
example, a method for treating cancers and individuals at risk
of developing cancers by administering an anti sense RNA of
LIM Kinase 1.
In another embodiment, the present invention indicates
that the expression of LIM kinase, one of the proteins that
modulates actin dynamics, is over expressed in denocarcinomatous prostatic epithelium and cancer cell lines.
In one embodiment of the present invention, there is provided an advantageous therapy for inhibiting the metastasis of
cancers cells, including, for example, breast, ovarian, lung,
and prostate cancer cells. More specifically, the invention, in
embodiments relates to the use of LIM kinase 1 antisense
RNA to reduce the synthesis of endogenous LIM kinase 1 in
prostate cancer cell lines. This reduction has been shown to
reduce the number of metastizing cancer cells.
In another embodiment of the invention, a partial reduction
of LIMKl altered cell proliferation by arresting cells at the
G2/M phase of the cell cycle. Data has also shown a changed
cell shape and the associated inhibition of the invasive tendencies of metastatic prostate cancer cells. Ectopic expression ofLIMKl promotes the acquisition of the invasive phenotype by benign prostate epithelial cells. Experimental data
provides evidence of a novel role ofLIMKl in regulating cell
division and in regulating the invasive properties of prostate
cancer cells.
In yet another embodiment of the invention, results indicate that the invasive properties of prostate cancer cells is not
mediated by phosphorylation of cofilin. Experimental data
correlates with the recent observations showing a metastasisassociated chromosomal gain of 7q11.2 in prostate cancer,
suggesting a possible gain in LIMKl DNA (7q 11.23).
Yet another embodiment of the instant invention comprises
partial amino acid and nucleotide sequences of LIMKl.
In still another embodiment of the present invention results
indicate that the anti sense RNA of LIM kinase 1 can be used
successfully in the functional inactivation of LIM kinase 1.
In other embodiments of the present invention, antisense
RNA may be used, for example, to inhibit gene function and
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to demonstrate that the LIMKl gene may find use, for
example, as a therapeutic target for developing effective cancer drugs.
In yet another embodiment results indicated, for the first
time, that LIMK 1 may find use as a novel target for anti sense
RNA mediated gene inactivation. Results also indicate that
the expression ofLIMK 1 may be used as a predictive marker
for prostate cancer cell metastasis.

PC3ASL (FIG. 4d) cells successively induced for 72 hours.
Cells were arrested at the G /S phase boundary and released.
FIG. 4b indicates the percentage of cells at different stages of
the cell cycle.
FIGS. 4c and 4d show cell cycle profiles of similar progression of PC3ASL and PC3LacZ cells to the Sand GiM
phase up to 6 hours after release, but only the PC3LacZ cells
of FIG. 4c continue to the G 1 and S phase, whereas the
PC3AL cells ofFIG. 4dundergo a GiM arrest from about 10
hours onwards. The reduced expression of LIMKl in PC3
cells is associated with the suppression of cell growth and cell
cycle arrest in the GiM phase.
FIG. Sa shows transfected cells that were successively
induced for from about 46 to about 50 hours before being
plated into the invasion chambers. Ectopic expression of
LIMKl in BPH-1 cells increased invasion significantly after
induction with ponasterone A, for from about 23 to about 25
hours, with about a 100% difference in invasion in different
cell lines. Data represents the mean±S.E. of quantitative
analysis of three independent assays (each from two different
clones oftransfected PC3 and BPH-1 cells).
FIGS. Sb and Sc, are bright field images of cells invaded to
the underside of the control and Matrigel membranes.
FIG. S d presents staining of LIMKl in BPHL and
BPHLacZ cells showing predominantly cytoplasmic distribution of LIMKl in BPHL cells. Nuclei were stained with
4,6-diamidino-2-phenylindole at 200x magnification. The
Reduced expression ofLIMKl is associated with a reversion
of the invasion ability of PC3 cells.
FIGS. 6a and 6b shows phase-contrast images of
PC3LacZ, (FIG. 6a) and PC3ASL cells, (FIG. 6b) after successive induction for 72 h.
FIGS. 6c, 6d, 6e, 6/, 6g and 6h, show dual staining of
continuously induced PC3LacZ cells (FIGS. 6c, 6e, and 6g)
and PC3ASL cells, (FIGS. 6d, 6/, and 6h) with Alexa 488conjugated phalloidin and anti-LIMKl, (FIGS. 6c and 6d),
anti-paxillin, (FIGS. 6e and 6j) or MTl-MMP, (FIGS. 6g and
6h) antibodies. Arrows indicate localization of LIMKl in
lamellipodia along with actin in FIG. 6c. Arrows in FIG. 6d
indicate accumulation of LIMKl between actin stress fibers
and cell boundary. The arrows in FIG. 6e indicate localization
of paxillin to the small adhesion points at the lamellipodia
along with actin. The redistribution of paxillin and accumulation in large areas between actin stress fibers and cell
periphery is show in FIG. 6/, and localization ofMTl-MMP
(also in the enlarged section) and actin to the lamellipodia is
shown in FIG. 6g. Scale bar, 10 µm.
FIGS. 6i and 6j, indicate phase contrast images of
BPHLacZ, 6i and BPHL, 6j showing the difference in growth
pattern. Here, reduced expression of LIMKl is associated
with changes in cell morphology, cytoskeleton organization,
and the invasive ability of PC3 cells.

BRIEF DESCRIPTION OF THE DRAWINGS
In a further effort to make the above-recited features and
aspects of the specific embodiments of the invention, clear,
more specific descriptions of the invention briefly summarized above may be had by reference to embodiments thereof
which are illustrated in the drawings. These drawings form a
part of the specification. It is to be noted, however, that the
drawings illustrate embodiments of the invention and therefore are not to be considered limiting in their scope.
FIG. la shows an immunoblot analysis ofLIMKl in total
lysates of human prostate cell lines.
FIGS. lb, le and ld show the expression of LIMKl of
normal/benign areas in prostrate tissues.
FIGS. le, lf, and lg show the expression of LIMKl of
cancerous glands in prostrate tissues.
FIGS. lb and le show hematoxylin/eosin-stained slides at
lOOx. magnification.
FIGS. ld and lg show normal and cancerous tissues at
200x magnification. Arrows in FIGS. le and ld indicate light
staining in basal cells in normal/benign areas. Arrows in
FI GS. lfand lg indicate intense staining in cells in cancerous
areas. Cell lines used were PrEC and prostate epithelial cells
in glyceraldehyde-3-phosphate dehydrogenase, GAPDH.
FIGS. 2a and 2b show the LIMKl concentrationinBPH-1
and PC3 cells before, FIG. 2a and after FIG. 2b immunoprecipitation with anti-LIMKl antibody. IB immunoblot. Sup,
supernatant.
FIG. 2c represents the in vitro phosphorylation ofrecombinant cofilin by LIMKl immunoprecipitated from PC3 cells.
FIG. 2d shows in vivo phosphorylation of cofilin in BPH-1
and PC3 cells, and is an Immunoblot analysis of cell lysates
before immunoprecipitation and shows the initial concentration of cofilin in both samples in the bottom panel of FIG. 2d.
FIG. 2e shows the immunoblot analysis of phosphorylated
cofilin or cofilin in crude cell extracts using anti-phosphocofilin or anti-cofilin antibodies.
FIGS. 3a and 3b show the RNA blot analysis ofLIMKl in
PC3ASL (a) and PC3LacZ (b) cells induced successively (+)
or not(-).
FIG. 3c shows the concentration ofLIMKl in transfected
PC3 cells harvested at different time points after successive
induction.
FIG. 3d shows the concentration of phosphorylated cofilin
(P-cofilin) or cofilin in transfected PC3 cells after continuous
induction. Despite the reduced concentration of LIMKl no
noticeable difference in phospho-cofilin concentration was
detected in PC3ASL cells Using a Western blot in glyceraldehyde-3-phosphate dehydrogenase GAPDH. LIMKl was
effectively reduced in PC3ASL cells by expression of antisense LIMKl, but there was no concurrent reduction in cofi!in phosphorylation.
FIG. 4a depicts a [3 H]thymidine incorporation in PC3ASL
and PC3LacZ cells induced successively (1) or not (N). Data
represents values relative to the initial time point (0 hours)
and as the mean±S.E of three independent experiments.
FIGS. 4b, 4c, 4d shows the flow cytometric analysis of cell
cycle transition in synchronized PC3LacZ (FIG. 4c) and
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The term "actin", as used herein refers to a protein of the
myofibril, localized in the I band; acting along with myosin
particles, it is responsible for the contraction and relaxation of
muscle. In the absence of salt, it becomes globular (G-actin),
and in the presence of potassium chloride and adenosine
triphosphate it polymerizes, forming long fibers (F-actin).
The term "administer" or "administration" refers to the
delivery of a pharamacological composition of the present
invention to an individual for the purpose of preventing or
treating of a cancer.
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The term "antisense RNA", as used herein refers to a
single-stranded RNA with a base sequence complementary to
a segment of another RNA molecule that can specifically bind
to the target RNA and inhibit its activity.
The term "antisense DNA", as used herein refers to a
single-stranded DNA with a base sequence complementary to
a segment of another DNA molecule that can specifically bind
to the target DNA and inhibit its activity.
The term "expression" (gene expression), as used herein
refers to the process by which a gene's coded information is
converted into the structures present and operating in the cell.
Expressed genes include those that are transcribed into RNA
but not translated into protein (e.g., transfer and ribosomal
RNA's).
The term "nucleic acid", as used herein is defined as family
of macromolecules, of molecular masses ranging upward
from 25,000, found in the chromosomes, nucleoli, mitochondria, and cytoplasm of all cells, and in viruses; in complexes
with proteins, they are called nucleoproteins. On hydrolysis
they yield purines, pyrimidines, phosphoric acid, and a pentose, either d-ribose or d-deoxyribose; from the last, the
nucleic acids derive their more specific names, ribonucleic
acid and deoxyribonucleic acid. Nucleic acids are linear (i.e.,
unbranched) chains of nucleotides in which the 5'-phosphoric
group of each one is esterified with the 3'-hydroxyl of the
adjoining nucleotide.
An "isolated nucleic acid" is a nucleic acid the structure of
which is not identical to that of any naturally occurring
nucleic acid or to that of any fragment of a naturally occurring
genomic nucleic acid spanning more than three separate
genes. The term therefore covers, for example, (a) a DNA
which has the sequence of part of a naturally occurring
genomic DNA molecule but is not flanked by both of the
coding sequences that flank that part of the molecule in the
genome of the organism in which it naturally occurs; (b) a
nucleic acid incorporated into a vector or into the nenomic
DNA of a prokaryote or eukaryote in a manner such that the
resulting molecule is not identical to any naturally occurring
vector or genomic DNA; (c) a separate molecule such as a
cDNA, genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and
(c) a hybrid gene, i.e., a gene encoding a fusion protein. The
term "oligonucleotide", as used herein is defined as a molecule comprised of two or more ribonucleotides, and in specific embodiments, more than three ribonucleotides. Its exact
size will depend upon many factors which, in tum, depend
upon the ultimate function and use of the oligonucleotide.
As used herein, the term "PCR" refers to the polymerase
chain reaction that is the subject of U.S. Pat. Nos. 4,683,195
and 4,683,202 to Mullis, as well as other improvements now
known in the art.
Two DNA sequences are "substantially homologous"
when, for example, at least about 7 5%, and more specifically,
at least from about 90% to about 95% of the nucleotides
match over the defined length of the DNA sequences.
Sequences that are substantially homologous can be identified by comparing the sequences using standard software
available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as
defined for that particular system.
The term "vector", as used herein refers to a DNA molecule
that replicates on its own in a host cell and can be used as a
vehicle in the laboratory for replicating other types of DNA.
Abbreviations used are: LIMKl, LIM kinase 1; NGF,
nerve growth factor; EGF, epidermal growth factor; BPH-1,
benign prostatic hyperplasia cells.

DESCRIPTION OF THE PREFERRED
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Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
To understand the role ofLIMKl in prostate cancer, BPH1, PrEC, LNCaP, DU145, P69, M21, M12, PC3AR, PC3Neo,
and PC3 cells were used as models for benign and cancerous
prostate cells. The above-mentioned cell lines may be used,
for example, in studies on the invasive behavior of prostate
cancer, which also exhibited increased expression ofLIMKl,
as compared with BPH-1. Because the function of LIMKl is
mediated through phosphorylation of cofilin in the reorganization of actin cytoskeleton, the status of the kinase activity of
immunoprecipitated LIMKl from several of the above-mentioned cell lines were studied, which confirmed that the
endogenous LIMKl was catalytically active. Interestingly, a
parallel increase in the concentration of endogenous phospho-cofilin was also noted in the cell lines. There was no
significant decrease in the concentration of phospho-cofilin
after enforced reduction of the expression ofLIMKl. Results
indicate that antisense-RNA-mediated LIMKl reduced the
expression of LIMKl and provides evidence of the involvement of LIMKl in regulation of growth of prostate cancer
cells, specifically at the G 2 /M phase of the cell cycle.
Results indicate a direct role ofLIMKl in G 2 /M phase of
the cell cycle, as a partial reduction of LIMKl expression
induced a GiM phase arrest, for example, in PC3ASL cells.
Consistent with the effect of LIMKl in the promotion of
cellular invasiveness, a visible alteration in the cell shape and
adhesion pattern was caused by a partial reduction in LIMKl
in prostate epithelial cells. In a specific embodiment,
PC3ASL cells showed discrete stress fibers, and a more flattened appearance that was typically observed after Rho activation. The effect ofLIMKl in facilitating cell invasion is not
mediated through the inactivating phosphorylation of cofilin.
This observation suggests a novel area of interaction between
LIMKl and other proteins that are involved in maintenance of
cell behavior such as invasion and locomotion. The presence
of two LIM domains and a PDZ domain at the amino-terminal
end of LIMKl suggests its possible interaction with other
proteins. It has been theorized that the effect of LIMKl is
accomplished through protein-protein interaction, a phenomenon that is sensitive to the stoichiometric balance and can be
altered with a partial reduction in LIMKl concentration. The
role ofLIMKl as the regulator ofboth the G 2 /M phase checkpoint and the invasive property of prostate cancer cells and a
chromosomal gain on 7q11.2, the region of localization of
LIMKl gene, for example, in metastatic prostate cancer suggests the possibility ofLIMKl as a cellular oncogene. Identification ofLIMKl as a potential promoter of prostate cancer
progression may facilitate further characterization of interacting partners involved in progression of primary tumors and
metastasis of advanced tumors and provide a novel therapeutic target for prevention of prostate cancer metastasis.
LIM kinase 1 (LIMKl) belongs to a novel dual specificity
(serine/threonine and tyrosine) kinase family that contains
two amino-terminal LIM domains. The LIMKl gene is
expressed predominantly in brain tissue and developing neural tissue. LIMKl gene deletion (microdeletion of chromosome 7ql 1.23) is typical for individuals with Williams's syndrome. Cofilin, a known actin-binding protein is considered
to be a potent regulator of actin protein dynamics based upon
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cofilin's activity in F-actin depolymerization. Cofilin is the
only known substrate of LIMKl. The regulatory function of
cofilin is inhibited by phosphorylation at the Ser-3 residue by
LIMKl, which has been known to lead to an accumulation of
F-actin. The catalytic activity of LIMKl is regulated by distinct members of the Rho protein subfamily of small GTPases
(Rho, Rae, and Cdc42), which controls actin filament dynamics and focal adhesion assembly in response to extra- and
intracellular stimuli. Rho, Rae, and Cdc42 induce formation
of stress fibers, assembly of lamellipodia and membrane
ruffles, and the regulation of filopodial protrusions, respectively. LIMKl has been shown to mediate specifically Racinduced actin cytoskeleton reorganization and focal adhesion
complexes. Rae-induced activation ofLIMKl is mediated by
PAK!, which phosphorylates LIMKl on its Thr508 residue. It
has been proposed that Rho and Cdc42-induced cytoskeletal
changes are mediated through phosphorylation ofLIMKl by
Rho-dependent protein kinase ROCK and Cdc42-regulated
protein kinase PAK4 and MRCKa.
The non-catalytic domain ofLIMKl contains two tandem
repeats of a LIM motif, a putative zinc binding motif, and a
PDZ domain, which contains two tandem nuclear exit signal
sequences. LIMKl also contains a nuclear localization signal-like basic cluster sequence. The non-catalytic domain of
LIMKl has been shown to effect cytoskeleton reorganization
independent of its kinase activity. Specific regions of the
non-catalytic domain (LIM or PDZ) inhibit neurite outgrowth
in differentiating PC12 cells responding to Ras, neuronal
growth factor (NGF) or a ROCK inhibitor without altering
endogenous LIMKl activity. This data suggests that the noncatalytic domain of LIMKl is involved in regulating cellular
processes though protein-protein interaction.
LIMKl also physically interacts through its LIM domain
with the cytoplasmic tail of neuregulins, a family of transmembrane proteins that functions as receptor tyrosine kinase
ligands. These proteins are known to be involved in the regulation of synapse formation and maintenance, cell proliferation, apoptosis, differentiation, and neuronal migration. Deletion experiments have shown that the lack of LIM and PDZ
domains enhances the effect ofLIMKl on actin cytoskeleton.
In addition, expression of a kinase-inactive form of the protein blocked the effect of the native LIMKl. These findings
suggest an inhibitory role of the non-catalytic domain in the
regulation of the kinase activity associated with LIMKl.
Reorganization of cytoskeleton is an aspect of motility,
detachment, and invasion of cancer cells. Individual members
of the Rho protein family, such as Rae and Cdc42, induce
distinct actin remodeling events, work together at the leading
edge of the cell, and coordinate lamellipodial and filopodial
extensions, whereas Rho activates accumulation of stress
fibers through activation of ROCK. The formation and stabilization of actin filaments provides the protrusive force for
cellular extensions at the leading edge of the migratory cells.
These events may affect the invasive behavior of the cancer
cells, as the inhibition of Rho kinase activity has been shown
to reduce the invasive progress of prostate cancer cells in vivo.
Rho proteins are activated by growth factor receptors and
their ligands, for example, EGF and NGF and their respective
receptors erbB2 and Trk. Cellular-erbB2 and Trk are often
over expressed and activated in various types of cancers
including prostate, lung, breast, and ovarian cancers. Furthermore, c-erbB2 was shown to enhance the invasiveness and
metastatic potential of cancer cells. Similarly, NGF and Trk
expressions in prostate cancer cells coincide with transformation to a malignant phenotype capable of invading the
perineural space and extra capsular metastasis to a distant
site. As evident from membrane ruffling and lamellipodia

formation, EGF- and NGF-induced invasion of prostate
tumor cells is mediated through Rae. It is likely that Racmediated activation of actin reorganization is mediated
through LIMKl. cDNA microarry and differential display
reverse-transcription PCR analyses indicate over expression
ofLIMKl mRNA and LIMKl as the elastin-linked gene in
prostate adenocarcinoma cells. Experimental data indicates
that LIMKl is over expressed in prostate adnocarcinomatous
tissues and in malignant prostate cell lines and may be necessary for the invasive property and growth of prostate cancer
cells. This effect is not mediated through the inactivation of
the phosphorylation of cofilin.
Recent studies show that LIMKl undergoes mitosis-specific activation by hyperphosphorylation, which is associated
with a concomitant increase in phosphorylation of cofilin.
LIMKl becomes activated in prometaphase and metaphase
and comes back to the basal level as cells enter telophase,
which suggests that a controlled activity of cofilin by phosphorylation and dephosphorylation is necessary for mitosis.
A direct role of LIMKl in promoting cellular invasion, a
hallmark of metastasis, is evident based on Matrigel-based
invasion assay analysis. A partial inhibition of LIMKl
reduced the percentage of invading cells down to the level
observed for BPH-1 cells. However, the effect of ectopic
expression with regards to LIMKl in BPH-1 cells on the
promotion of the invasion was more pronounced and significantly higher than the highly metastatic PC3 cells, suggesting
a possible role for LIMKl in the acquisition of metastatic
behavior of prostate tumors. An increased expression of
LIMKl in metastatic prostate tumors, may indicate an association ofLIMKl expression with advanced prostate cancer.
It is possible that the effect of growth factors on the increased
invasion is mediated through LIMKl in advanced prostate
cancer in which specific receptors for NGF and EGF are over
expressed. However, it is unclear how the ectopic expression
of LIMKl promotes cellular invasion in BPH-1 cells, in
which the upstream effectors ofLIMKl may not be activated
without specific extra-cellular signals.
Manimalian LIM kinase 1 is involved in the reorganization
of the actin cytoskeleton through the inactivating phosphorylation of the ADF family protein cofilin that depolymerizes
actin filaments. Maintenance of actin dynamics in an ordered
fashion is required for the stabilization of cell shape and for
the promotion of cell motility of some cell types. Cell shape
and promotion of cell motility are two phenomena that may
become altered during acquisition of the metastatic phenotype by the cancer cell. Data indicates that when LIMKl is
over-expressed in manimalian prostate tumors and prostate
cancer cells, the concentration of phosphorylated cofilin is
higher in metastatic prostate cancer cells.
Anti sense agents are tools for use in inhibiting the expression of target genes in a sequence-specific mamier and have
found use in functional genomics, target validation, and for
therapeutic purposes. Different types of anti-mRNA strategies, for example, the use of single stranded antisense-oligonucleotides, the triggering of RNA cleavage through catalytically active oligonucleotides referred to as ribozymes, and
RNA interference induced by small interfering RNA molecules, have been attempted. The successful use of antisense
agents may depend, for example, on identifying accessible
sites of the target RNA for oligonucleotide binding, protecting the antisense agents from nucleolytic attack, preventing
their cellular uptake, and providing for the correct intracellular localization. Some success has been shown with chemically modified nucleotides, for example, alkyl modifications
at the 2' position of the ribose. These chemically modified
nucleotides have shown improved serum stability, higher tar-
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get affinity and low toxicity. In addition, RNA-cleaving
ribozymes and deoxy-ribozymes, along with the use of
21-mer double-stranded RNA molecules for RNA interference applications in mammalian cells has shown efficiency in
the suppression of the expression of specific genes.
Antisense approaches differ from conventional drugs,
most of which bind to proteins and thereby modulate their
function. In contrast, antisense agents act at the mRNA level,
preventing its translation into protein. Antisense-oligonucleotides (AS-ONs) pair with their complementary mRNA,
whereas ribozymes and DNA enzymes are catalytically
active oligonucleotides that not only bind, but can also cleave,
their target RNA. Recently, progress that been made with the
development and use of chemically modified nucleotides that
stabilize oligonucleotides against nucleolytic degradation
and enhance their target affinity. In addition RNA interference may be used as an efficient method of suppressing gene
expression in mammalian cells by the use of 21-23 mer small
interfering RNA (siRNA) molecules.
Antisense-oligonucleotides combine many desired properties, for example, broad applicability, direct utilization of
sequence information, rapid development at low costs, high
probability of success and high specificity compared to alternative technologies for gene functionalization and targeting.
Anti sense oligonucleotides have also proved useful in animal
models for therapeutic purposes.
Antisense-oligonucleotides may, for example, consist of
from about 15 to about 20 nucleotides, which are complementary to their target mRNA. Phosphorothioate (PS) oligodeoxynucleotides are one type of oligonucleotide used for
inhibiting gene expression. In this class of oligonucleotide,
one of the non-bridging oxygen atoms in the phophodiester
bond is replaced by sulfur. The introduction of phosphorothioate linkages into oligonucleotides was primarily
intended to enhance their nuclease resistance.
Phosphorothioate DNAs have a half-life in human serum
of from about 9 to about 10 hours compared to about 1 hour
for unmodified oligodeoxynucleotides. In addition to
nuclease resistance, phosphorothioate DNAs form regular
Watson-Crick base pairs, activate RNase H, carry negative
charges for cell delivery and display attractive pharmacokinetic properties.
Another class of antisense oligonucleotides contains alkyl
modifications at the 2' position of the ribose. 2'-0-methyl and
2'-0-mehtoxy-ethyl RNA are members of this class. 2'-0alky RNA oligonucleotides do not recruit RNase H, their
antisense effect is due, for example, to a steric block of
translation. Other antisense oligonucleotides modifications
may include, for example, C-5 propyne, 2'-0-aminopropyl,
and dipyridophenazine-DPPZ
A chemically synthesized anti sense nucleic acid molecule
or ribozyme may be introduced into a cell by any of a variety
of methods know in the art (Sambrook et al., supra, 1989, and
in Ausubel et al., Current Protocols in Molecular Biology,
Hohn Wiley and Sones, Baltimore, Md. (1994), incorporated
herein by reference in its entirety), including, for example,
transfection, microinjection, electroporation or the use of
liposomes. In addition, it is recognized by those skilled in the
art that naked nucleic acid molecules are taken up by cells in
vivo and, therefore, the antisense nucleic acid molecule of the
invention may be administered, for example, directly to the
region containing the cancer cells. More specifically, antisense nucleic acid molecules may be introduced into a cell
using methods that do not require the initial introduction of an
encoding nucleic acid molecule into a vector. For example, a
nucleic acid molecule encoding an antisense LIMK 1 molecule can be introduced into a cell using a cationic liposome,

which also can be modified with specific receptors or ligands
as described above (Morishita et al., J. Clin. Invest., 91:25802585 (1993), incorporated herein by reference; see, also,
Nabel et al., supra, 1993)). In addition, a nucleic acid molecule may be introduced into a cell using adenovirus-polylysine DNA complexes (see, for example, Michael et al., J.
Biol. Chem., 268:6866-6869 (1993), and incorporated herein
by reference in its entirety).
Embodiments of the present invention also includes
nucleic acids that hybridize under stringent hybridization
conditions, as defined herein, to all or a portion of the nucleotide sequence represented by SEQ ID NO: 1 or its complement. The hybridizing portion of the hybridizing nucleic acid
varies from about 80%, and for example, at least 95%, or at
least 98% identical to the sequence of a portion or all of a
nucleic acid encoding a polypeptide, or its complement.
Hybridizing nucleic acids of the type described herein can be
used, for example, as a cloning probe, a primer (e.g, a PCR
primer), or a diagnostic probe. Hybridization of the oligonucleotide probe to a nucleic acid sample typically is performed under stringent conditions. Nucleic acid duplex or
hybrid stability is expressed as the melting temperature or
Tm, which is the temperature at which a probe dissociates
from a target DNA. This melting temperature is used to define
the required stringency conditions. If sequences are to be
identified that are related and substantially identical to the
probe, rather than identical, then it is useful to first establish
the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g., SSC
or SSPE).
Then, assuming that 1% mismatching results in a 1° C.
decrease in the Tm, the temperature of the final wash in the
hybridization reaction is reduced accordingly (for example, if
sequences having >95% identity with the probe are sought,
the final wash temperature is decreased by 5° C.). In practice,
the change in Tm can be from about 0.5° C. to about 1.5° C.
per 1% mismatch. Stringent conditions involve hybridizing at
about 68° C. in 5x SSC/5xDenhardt's solution/1.0% SDS,
and washing in 0.2xSSC/0.1 % SDS at about 37° C. Moderately stringent conditions include washing in 3xSSC at about
42° C. The parameters of salt concentration and temperature
can be varied to achieve the optimal level of identity between
the probe and the target nucleic acid. Additional guidance
regarding such condition parameters are readily available in
the art, for example, by Sambrook et al., 1989, Molecular
Cloning, A Laboratory Manual, Cold Spring Harbor Press,
N.Y.; and Ausubel et al. (eds.), 1995, Current Protocols in
Molecular Biology, (John Wiley & Sons, N.Y.) at Unit 2.10,
both of which are incorporated herein by reference in their
entirety.
Any individual domain, for example, an LIM, a PDZ, or a
LIM kinase domain, individually or in combination, may be
used and/or modified while retaining the activity of the
polypeptide.
As used herein, "percent homology" of two amino acid
sequences or of two nucleic acids may be determined using
the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci.
USA 87:2264-2268, 1990), modified as in Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993), both
of which are incorporated herein by reference in their entirety.
Such an algorithm is incorporated into the NBLAST and
XBLAST programs of Altschul et al. (J. Mo!. Biol. 215:403410, 1990), incorporated herein by reference in its entirety.
BLAST nucleotide searches are performed with the
NBLAST program, score=lOO, word length=12, to obtain
nucleotide sequences homologous to a nucleic acid molecule
of the invention. BLAST protein searches are performed with
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the XBLAST program, score=50, word length=3, to obtain
amino acid sequences homologous to a reference polypeptide
(e.g., SEQ ID NO: 2). To obtain gapped alignments for comparison purposes, Gapped BLAST is utilized as described in
Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997),
incorporated herein in its entirety. When utilizing BLAST
and Gapped BLAST programs, the default parameters of the
respective programs (e.g., XBLAST and NBLAST) are used.
See http://www.ncbi.nlm.nih.gov.
Such a composition typically contains from about 0.1 to
about 90% by weight (such as 1 to 20% or 1 to 10%) of a
therapeutic agent of the invention in a pharmaceutically
acceptable carrier. Solid formulations of the composition for
administration may contain suitable carriers or excipients,
such as corn starch, gelatin, lactose, acacia, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate,
calcium carbonate, sodium chloride, or alginic acid. Disintegrators that can be used include, without limitation, microcrystalline cellulose, corn starch, sodium starch lycolate and
alginic acid. Lubricants that may be used include magnesium
stearates, stearic acid, silicone fluid, talc, waxes, oils, and
colloidal silica.
Injectable formulations of the compositions may contain
various carriers such as vegetable oils, dimethylacetamide,
dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl
myristate, ethanol, polyols (glycerol, propylene glycol, liquid
polyethylene glycol, and the like). For intravenous injections,
water soluble versions of the compositions may be administered by the drip method, whereby a pharmaceutical formulation containing an antifungal agent and a physiologically
acceptable excipient is infused. Physiologically acceptable
excipients may include, for example, 5% dextrose, 0.9%
saline, Ringer's solution or other suitable excipients. Intramuscular preparations, e.g., a sterile formulation of a suitable
soluble salt form of the compositions, can be dissolved and
administered in a pharmaceutical excipient such as Water-forInjection, 0.9% saline, or 5% glucose solution. A suitable
insoluble form of the compositions may be prepared and
administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long
chain fatty acid (e.g., ethyl oleate).
A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to
about 20%, e.g., 5 to 10%, in a carrier such as a pharmaceutical cream base. Various formulations of topical use include
drops, tinctures, lotions, creams, solutions and ointments
containing the active ingredient and various supports and
vehicles. The optimal percentage of the therapeutic agent in
each pharmaceutical formulation varies according to the formulation itself and the therapeutic effect desired in the specific pathologies and correlated therapeutic regimens.
Conventional methods, known to those of ordinary skill in
the art of medicine, can be used to administer the pharmaceutical formulations(s) to the patient. For example, any known
viral vector or any known method for delivering RNA to
prostate cells may be used. Typically, the pharmaceutical
formulation will be administered to the patient by applying to
the skin of the patient a transdermal patch containing the
pharmaceutical formulation, and leaving the patch in contact
with the patient's skin generally for from about 1 to about 5
hours per patch. Other transdermal routes of administration
(e.g., through use of a topically applied cream, ointment, or
the like) can be used by applying conventional techniques.
The pharmaceutical formulation( s) can also be administered
via other conventional routes (e.g., oral, subcutaneous, intrapulmonary, transmucosal, intraperitoneal, intrauterine, sublingual, intrathecal, or intramuscular routes) by using stan-

dard methods. In addition, the pharmaceutical formulations
can be administered to the patient via injectable depot routes
of administration such as by using 1-, 3-, or 6-month depot
injectable or biodegradable materials and methods.
Regardless of the route of administration, the therapeutic
agent typically is administered at a daily dosage of from about
0.01 mg/kg to about 30 mg/kg of body weight of the patient,
for example, from about 1 mg/kg to about 5 mg/kg. The
pharmaceutical formulation can be administered in multiple
doses per day, if desired, to achieve the total desired daily
dose.
The effectiveness of the method of treatment can be
assessed by monitoring the patient. For example, a decrease
in the spread or proliferation of prostate cancer cells can be
detected by monitoring the patient for a dose-dependent
reduction in prostate-specific antigen (PSA) levels. Dosedependent reductions in PSA correlate with a dose-dependent
decrease in the spread of prostate cancer cells.
There are several techniques and methods known in the art
for in vivo identification and monitoring of cancer cell
metastasis. For example, bone scintigraphy may be used in
monitoring. Prostate specific membrane antigen (PSMA)
scintigraphy, is known and is one of the most sensitive imaging techniques for the initial detection of bone metastases and
is widely used in the staging of prostatic cancer. PSMA is
found in normal prostatic epithelial cells and is elevated in
prostate cancers, especially in poorly differentiated, metastatic, and hormone refractory carcinomas. Tumor scintigraphy may be used for, but is not limited to, detection of certain
primary, metastatic, and recurrent tumors, evaluation of
abnormal imaging and non-imaging findings in patients with
a history of certain tumors, and reassessment of patients for
residual tumor burden after therapy. Bone is the most common site of circulatory (or haematogenous) metastases from
prostate cancer. Bony metastases are found in 85% of patients
dying of the disease. Radionuclide scintigraphy using a radioactively labeled chemical is administered to the patient and is
taken up in areas of increased bone turnover or growth.
Although sensitive, this technique is not specific and falsepositives may be obtained in cases of recent bone trauma,
degenerative joint disease or Paget's disease. Other imaging
techniques include single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI),
and magnetic resonance spectroscopy (MRS). ProstaScint
Imaging is based on using planar and SPECT imaging to map
the uptake of capromab pendetide that has been labeled with
a radionucliotide. Capromab pendetide is a monoclonal antibody that targets prostate-specific membrane antigen, a transmembrane glycoprotein that has been thoroughly characterized because of its role as a marker for prostate cancer and
metastases. As with all scintigraphic studies, correlation of
findings with results of other imaging and non-imaging
modalities, as well as with clinical information, is necessary
for maximum diagnostic yield.
Prostate Specific Antigen (PSA) measurements are known
in the art and have been shown to be accurate and costeffective predictors of prostate cancer cell proliferation.
In one embodiment the composition may, for example, be
presented in a pack or dispenser device, such as an FDA
approved kit, which may contain one or more unit dosage
forms of the active ingredient. The pack may, for example
comprise metal or plastic foil. The pack or dispenser device
may be accompanied by instructions for administration.
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Example 1

beads (Sigma) using the procedure as described, and the
products were resolved in a from about a 10 to about a 14%
solution ofSDS-PAGE. Labeled cofilin was detected by autoradiography and Phosphorlmager analysis. Recombinant
cofilin was expressed in Escherichia coli as a His-tagged
fusion protein by cloning the open reading frame of human
cofilin into the T7 polymerase driven pET30Ek/LIC
(Novagen) expression vector using specific primers (F,
5'-GACGACGACAAGATGGCCTCCGGTGTGGCTG-3'
(SEQ ID NO. 2), and R, 5'-GAGGAGAAGCCC GGTTCACAAAGGCTTGCCC-3' (SEQ ID NO. 3)). The expression
construct was used to transform BL21 (DE3) E. coli cells.
Transformed cells were induced with 1 mM isopropyl-1-thio~-D-galactopyranoside at 25° C., and the expressed cofilin
was purified through a Nickel affinity colunm.

Cell Culture, Transfection, and Isolation of Stable
Cell Line
5

The following cell lines, including, PC3, DU145, LNCaP,
PrEC, BenignProstatic Hyperplasia (BPH-1), P69, M21, and
M12 weremaintainedinRPMI (DU145, LNCaP, P69, M21,
and M12), Ham-12 (PC3), DMEM (BPH-1) and in the specific medium (PrEC) and grown to log phase before being
used. PC3 cells were transfected using LipofectAMINE™
with the open reading frame of the Lacz gene or the antisense
cDNA of the coding sequence of LIMKl (1.94 kilobases),
both cloned into an ecdysoneinducible mammalian expression vector pIND. BPH-1 cells (benign pro static hyperplasia)
were transfected with the open reading frames of LIMKl or
Lacz cloned in pIND. Cells were cotransfected with the
vector p VRxR that encodes the subunit of a heterodimer of
the ecdysone and the retinoid X receptor to establish stable
cell lines (PC3ASL and PC3LacZ) capable of expressing
antisense LIMKl RNA or Lacz when induced with an ecdysone analogue, ponasterone A. Double stable clones were
selected using from about 450 µg/ml to about 550 µg/ml
Geneticin™ and from about 45 µg/ml to about 55 µg/ml
Zeocin™. Stable transfected cells were continuously induced
by adding from about 4 µM to about 6 µM ponasterone A for
from about 20 to about 24 hours.

10

15

Example 4

20

25

Example 2
30

Immunoblotting, Immunohistochemistry, and
Immunofluorescence
Total cell lysates were resolved in a from about 10 to about
a 14% solution ofSDS-PAGE and subjected to immunoblotting using anti-LIMKl, anti-cofilin, or anti-phospho-cofilin
antibodies. Anti-glyceraldehyde-3-phosphate dehydrogenase antibody was simultaneously used as an internal control.
Goat anti-mouse or anti-rabbit antibody was used as the secondary antibody. Paraffin-embedded tissue sections of norma! and malignant human prostate were subjected to a pepsin-based antigen retrieval protocol followed by incubation
with anti-LIMKl antibody. A biotinylated multi-link goat
anti-immunoglobulin for mouse, rabbit, guinea pig, and rat
was used as the secondary antibody. Positive signals were
detected by horseradish peroxidase-conjugated streptavidin
and 3,3'-diaminobenzidine (DAB) as the chromogen. For
indirect immunofluorescence, PC3ASL and PC3LacZ cells
were plated on poly-L-lysine-coated glass cover slips and
continuously induced for from about 70 to about 74 hours.
Cells were permeabilized and dually stained withA!exa Fluor
488-conjugated phalloidin and anti-LIMKl, anti-paxillin, or
anti-MTl-MMP antibodies. Cy3-conjugated anti-mouse or
anti-rabbit antibody (Molecular Probes) was used as the secondary antibody. Fluorescent images were captured using a
laser-scanning confocal microscope.
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Example 5
Invasion Assay
40

45
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BPH-1 and PC3 cells were cultured in the presence of 1.5
mCi of [32P]orthophosphate forr from about 10 hours. Equal
amounts of total cell lysates were subjected to immunoprecipitation with anti-cofilin antibody and protein A-agarose

Cells were plated in serum-free media (containing ponasterone A for transfected cells) as a control and Matrigelcoated membrane containing invasion chambers. Cells were
incubated at about 3 7° C. for from about 20 to about 24 hours
in a co2 incubator using from about a 4 to about a 6% fetal
bovine serum in the lower chamber as the chemoattractant.
Invading cells were stained with Diff-Quick™ stain and
counted. The percentage of metastasizing cells that invaded
through the Matrigel-coated membranes was calculated by
comparison with the cells passed through the membranes in
the control chambers. The results are shown in FIG. 5.
Example 6

55

Example 3
In Vivo Phosphorylation, Expression of
Recombinant Protein, and Immunecomplex Kinase
Assay

For immune complex kinase assay, LIMKl was immunoprecipitated from PC3 cells cultured under regular conditions
using anti-LIMKl antibody and protein G-agarose (Sigma)
beads. Protein G-agarose beads bound to the immune complex were re-suspended in kinase assay buffer comprising
from about 45 to about 55 mM HEPES, a pH of from about 7 .0
to about 8.0, from about 100 to about 200 mM NaCl, from
about 45 to about 55 M ATP, from about 4 to about 6 mM
MgCl 2 , from about 4 to about 6 mM MnCl 2 , from about 9 to
about 11 mM NaF, from about 0.5 to about 1.5 mM Na 3 V04 ,
from about 2 to about 4 nM [y- 32 P]ATP) and incubated at
about 30° C. for from about 15 to about 25 minutes with from
about 9 to about 11 µg of recombinant cofilin as the substrate.
The reaction mixture was resolved in a from about 12% to
about a 16% solution of SDS-PAGE, and phosphorylated
cofilin was detected by autoradiography and Phosphorlmager
analysis.
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H]Thymidine Incorporation, Cell synchronization,
and Fluorescence-Activated Cell Sorter Analysis

Asynchronous PC3LacZ and PCASL cells were incubated
with about 1 µCi of [3 H]thymidine in the presence or absence
of ponasterone A. At about 10 minute time intervals after
induction, cells were treated with a 5% trichloroacetic acid
solution and lysed using a 0.5 N NaOH solution. Incorporation of [3 H]thymidine to DNA was measured in a scintillation
counter (Beckman LS 5000 TD). For cell cycle analysis,
PC3LacZ and PC3ASL cells induced at from about every 20
to about every 24 hours, were synchronized at the G /S phase
boundary by a double thymidine block by treating them with
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a solution of from about 1 to about 3 mM thymidine for from
about 22 to about 26 hours followed by a release of from about
7 to about 9 hours in fresh growth medium and successive
re-treatment with thymidine (2 mM) for about 16 hours. The
cells were then released to enter the cell cycle in fresh growth
medium and harvested at specified time intervals. The cells
were fixed in a solution of from about 0.5 to about 1.5%
paraformaldehyde in phosphate-buffered saline (PBS),
washed in PBS, permeabilized with a solution of from about
0.2% to about 0.3% saponin in PBS, and treated with from
about 0.5 mg/ml to about 1.5 mg/ml of a solution ofRNase (1
mg/ml) at from about 37° C. The cells were washed in phosphate-buffered saline and stained with a from about 350 to
about a 450 µg/ml solution of propidium iodide at about 37°
C. for from about 25 to about 35 minutes. The cells were
analyzed in a flow cytometer, and the raw data was analyzed
using Modfit (BD Biosciences) software.

(FIG. 2, d and e), which demonstrates a parallel increase in
phosphorylated cofilin within these cells.

Example 7

Example 8
5

A Partial Inhibition of LIMKl Expression Did not
Result in Reduced Phosphorylation of Cofilin
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LIMKl is Over Expressed in Cancerous Prostate
Cells and Tissues and is Catalytically Active
To confirm the differences in the expression of LIMKl in
prostate cancer, the expression profile ofLIMKl was monitored in various prostate cell lines, for example, PC3, DU145,
LNCaP, PrEC, Benign Prostatic Hyperplasia (BPH-1), P69,
M21, and M12 were maintained in RPMI (DU145, LNCaP,
P69, M21, and M12), Ham-12 (PC3), DMEM (BPH-1) and
prostate tissues. Results of the monitoring indicated an
increased expression of LIMKl in aggressive metastatic
prostate epithelial cells and in some prostatic adenocarcinomas (FIG. l). The concentration ofLIMKl in some cancerous
prostate cell lines (M21 and M12) increased proportionately
with increasing tumorigenic and aggressive properties when
compared with normal prostate epithelial cells, P69 and
BPH-1 cells (FIG. la). An increase of from about 200% to
about 300% expression ofLIMKl was noted in tumorigenic
cells, LNCaP, M21 and metastatic cells, PC3, DU145, and
M12 prostate cancer cells when compared with BPH-1 and
P69 (non-tumorigenic) cells (FIG. la). Compared with prostate epithelial cells, the expression of LIMKl was, for
example, from about 500% to about 1000% higher in the
metastatic prostate cancer cells, PC3 and M21 (FIG. la).
Consistent with these findings, immunohistochemical analysis indicated a higher expression of LIMKl in some cancerous glands in prostatic epithelium (FIGS. le, f, and g). The
expression ofLIMKl in prostate tissues was localized to the
basal cells in benign glands (arrows in FIGS. lb, c and d)
compared with a widespread expression and staining in both
the cytoplasm and the nucleus in the epithelial cells of cancerous glands (arrows in FIGS. le, f, and g). These results
indicate a correlation between over expression ofLIMKl and
phenotypic differences in prostate tissues.
The expressed LIMKl in prostate cancer cells was catalytically competent because immunoprecipitated LIMKl
(FIG. 2, a and b) from PC3 cells was capable of phosphorylatingrecombinant cofilin (FIG. 2c ), the only known substrate
ofLIMKl. To determine whether the increased expression of
LIMKl was associated with an increased phosphorylation of
endogenous cofilin, the phosphorylation status of the native
cofilin in BPH-1 and PC3 cells was studied using in vivo
phosphorylation and immunoblotting techniques. Although
no significant difference in the expression of cofilin was noted
in these two cell lines an increase of from about 60% to about
80% in the phosphorylated cofilin was noted in the PC3 cells
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To understand the possible role of over expressed LIMKl
in the acquisition oftumorigenic and metastatic phenotypes,
antisense-RNA mediated functional inactivation of LIMKl
was used; subsequently, a PC3ASL cell line was generated
which was capable of expressing antisense LIMKl RNA after
induction with an ecdysone analogue, ponasterone A. A time
course study using PC3ASL cells and a control transformed
cell line, PC3LacZ, after continuous induction for from about
20 to about 22 hours for a total of 72 hours, indicated the
maximum expression ofLIMKl antisense transcript at about
72 hours, which was associated with a concurrent decrease in
the concentration of the sense LIMKl transcript only in the
induced PC3ASL cells (FIG. 3a). No decrease in the LIMKl
transcript was apparent in any of the PC3LacZ cells induced
or not or in un-induced PC3ASL cells (FIG. 3, a and b). A
parallel reduction in the LIMKl protein concentration confirmed the decreased synthesis of LIMKl in PC3ASL cells
(FIG. 3c). Immunoblot analysis using anti-cofilin or antiphospho-cofilin antibodies revealed no simultaneous
decrease in the concentration of phosphorylated cofilin in
PC3ASL cells (FIG. 3d). This observation suggests, for
example, that, the residual LIMKl can be catalytically more
efficient andmaintain an increased concentration of phosphorylated cofilin or the enhanced phosphorylation of cofilin was
not mediated by LIMKl. Although cofilin is the only known
substrate ofLIMKl, it can be phosphorylated by other serine/
threonine kinases, such as LIMK2 and TESK1/TESK2.
Example 9

40

45

50

55

60

65

Reduced Expression of LIMKl Retarded Cell
Proliferation by Arresting Cells at the GiM Phase of
the Cell Cycle
The effect of a reduced expression ofLIMKl with regard to
cell proliferation and cell cycle progression was studied.
LIMKl is expressed in a growth phase-dependent manner,
which suggests, for example, its possible involvement in the
regulation of cell growth.
The growth pattern of induced and non-induced PC3ASL
and PC3LacZ cells by [3 H]thymidine incorporation assay
was monitored. Results indicated that the inhibition of
expression of LIMKl led to a block in [3 H]thymidine incorporation only in PC3ASL cells after about 48 hours of continuous induction (FIG. 4a), signifying a growth arrest in
PC3ASL cells. A possible role, for example, of active LIMKl
in regulating mitosis has been suggested also, based on the
studies that have shown that the LIMKl activity fluctuates
with cell cycle progression and attains a maximum level
during mitosis when LIMKl becomes hyperphosphorylated,
presumably by mitotic Cdks. Induced PC3ASL and PC3LacZ
cells synchronized at the G /S phase boundary by double
thymidine block were used and the cell cycle progression was
monitored by harvesting cells at different time points after the
release of the block. At about 0 hours, from about 7 5 to about
78% of the PC3ASL and PC3LacZ cells had progressed to the
G/S phase of the cell cycle. The remaining from about 22%
to about 25% of cells had progressed to the G2/M phase of the
cell cycle, as determined by the higher DNA content in a
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subpopulation of PC3 cells with inherent chromosomal gain.
Afterthe release ofthymidine block, both cell types exhibited
progression through the S phase, about 60% of the cells and
for the G 2 /M phase, about 30% of the cells during the next 6
hours. PC3LacZ cells cycled through the G 1 phase as a
gradual increase in the percent of cells in the G 1 phase was
noted with a concurrent decrease in the total percent of cells
in the Sand G 2 /M phases from about the 6'h to about the 14th
hours (FIG. 4, band c ). In contrast, the PC3ASL cells started
to accumulate in the GiM phase during this time with about
50% of the cells at 14 hours, indicating a G 2 /M phase arrest in
these cells (FIG. 4, band d). The absence of any blockage in
the cell cycle progression of the PC3LacZ cells (FIG. 4, band
c) confirms that a threshold concentration of LIMKl is necessary for the passage of cells through the GiM phase of the
cell cycle. These results are also consistent with the [3 H]
thymidine incorporation data, indicating a growth arrest in
the PC3ASL cells.

in PC3 cells was monitored. The induced PC3LacZ cells
exhibited cell morphology typically observed in PC3 cells,
with smooth edges and the occasional presence of the filopodial spike-like structures extended from one or both ends of
the cell and, in some cases, a phase dense border, characteristic of ruffling lamellipodia around an extensive area of the
cell periphery (FIG. 6a, arrows). From about 70 to about 90%
of the induced PC3ASL cells, however, showed a more flattened and irregular shape, with several dark patches at the
periphery of the cells (arrows in FIG. 6b) that appear to be
possible adhesion points. Fluorescent staining of actin
cytoskeleton indicated a prominent actin meshwork, characteristic of lamellipodia formation at the leading edge of the
induced PC3LacZ cells (FIG. 6c, middle and right); this
meshwork was also typical of parental PC3 cells (data not
shown) and of motile cells. Immunolocalization of LIMKl
(FIG. 6c) showed a perinuclear distribution, with distinct
targeting to the ruffles at the leading edge of these cells
(arrows in FIG. 6c, left). In contrast, from about 70 to about
90% of induced PC3ASL cells showed a predominant formation of discrete stress fibers and focal adhesions typically
observed in non-motile adherent cells (FIG. 6d, middle and
right). Distribution of LIMKl in these cells was also perinuclear, with one or more broad areas of accumulation (arrows) at the periphery of the cell (FIG. 6d, left).
Changes in the adhesion system of the PC3ASL and
PC3LacZ cells were investigated by monitoring immunolocalization of paxillin, an adapter protein associated with focal
adhesions of adherent cells (FIG. 6e). PC3LacZ cells showed
the presence of paxillin as broad areas surrounding the
nucleus and small adhesion sites at the cell periphery, which
overlapped the actin meshwork that forms the lamellipodia
(arrows in FIG. 6e, left, middle, and right). In contrast, paxillin was more centrally localized in PC3ASL cells, with
frequent accumulation in broad areas between the actin meshwork (arrows) representative of stress fibers (FIG. 6, left,
middle, and right) and the cell boundary.
Published reports indicate an elevated expression of the
membrane-type matrix metalloproteinase MTl-MMP in
invasive prostate cancer cells such as PC3 and DU145.
Because the localization of MTl-MMP to lamellipodia has
been correlated with the invasive properties of cells, the distribution of this protein in PC3ASL and PC3LacZ cells was
monitored. Distribution ofMTl-MMP in induced PC3LacZ
was localized to the perinuclear and to the lamellipodia along
with actin (arrows in FIG. 6g, left, middle, and right) but
mainly in the perinuclear region in PC3ASL cells FIG. 6h)
and between actin stress fibers (enlarged box). These results
indicate that a reduction in LIMKl concentration induced
beneficial changes in the actin cytoskeleton reorganization,
the adhesion pattern, and localization of MTl-MMP in PC3
cells.
An increase in the expression of LIMKl showed a correlation with the aggressiveness of metastasizing cancer cells.
For example, expression of LIMKl was higher in metastatic
PC3 cells and M12 cells when compared with the less-aggressive LNCaP and M21 cells. Consistent with this observation, expression ofLIMKl was significantly higher in cancerous prostate tissues compared with histologically normal
pro static epithelium. This may explain the chromosomal gain
on 7q11.2-q31 that is predominantly found in metastasis of
prostate tumors. Molecular cytogenetic analysis of pro static
adenocarcinomas indicated an increase in the number of
patients showing a gain of chromosome 7pq with increasing
tumor volume. These chromosomal alterations are also found
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Reduced Expression of LIMKl Abolished the
Invasive Behavior of Prostate Cancer Cells
The inhibition ofLIMKl expression on the invasive property of PC3 cells was studied using an in vitro invasion assay.
The untransfected PC3 cells indicated that a from about 200%
to about a 300% increase of the untransfected PC3 cells were
invasive and migrated through the Matrigel compared with
the non-invasive BPH-1 cells (FIG. 5, a and b). A partial
inhibition ofLIMKl expression in PC3ASL cells resulted in
a from about 350 to about 550% decrease in the percent of
invaded cells compared with wild type PC3 and PC3LacZ
cells (transfection control). This was comparable to the percent ofBPH-1 cells invaded through the membranes. Results,
as shown in FIG. 3, confirm that LIMKl is necessary to carry
out the invasive function of PC3 cells.
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The effect of the ectopic expression ofLIMKl and Lacz,
as the control in non-invasive BPH-1 cells was studied in an
effort to confirm the role ofLIMKl in promoting invasiveness
of prostate epithelial cells. Expression of LIMKl in transfected BPH-1 cells after induction by ponasterone A showed
predominantly cytoplasmic localization of LIMKl (FIG. 5)
and altered the growth pattern from a clustered and patchy
appearance (BPHLacZ)) to a more uniform distribution of
single cells (BPHL) (FIG. 6, i andj). Expression ofLIMKl in
ponasterone A-treated BPHL cells increased by 1300% the
percentage ofinvasive cells when compared with BPH-1 cells
expressing Lacz (FIG. 5, a and c). This suggests the acquisition of a new invasive phenotype by the non-invasive prostate
cells. Results provided evidence that LIMKl may be one of
the key proteins that promotes invasiveness and indicates that
the increased expression of LIMKl in PC3 cells may render
them metastatic.
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Altered Expression of LIMKl Changes Cell
Morphology and Organization of Actin Cytoskeleton
The dynamic regulation of the actin cytoskeleton and the
extra-cellular matrix degradation are both required for the
invasion process of tumor cells to progress. Reductions in
these processes following the reduced expression of LIMKl
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in primary tumors that showed progression after radical prostatectomy, suggesting a possible correlation of LIMKl
expression as a biomarker for
While the invention has been described, disclosed, illustrated and shown in cancer terms of certain embodiments or
modifications which it has presumed in practice, the scope of
the invention is not intended to be, nor should it be deemed to
be, limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are particularly reserved especially as they fall within the breadth
and scope of the claims here appended.

-continued
SEQUENCE LISTING

GTTCGACGAGGAGACCCAGAGGACGTTCCTCAAGGAGGTGAAGGTCA
TGCGATGCCTGGAACACCCCAACGTGCTCAAGT
TCATCGGGGTGCTCTACAAGGACAAGAGGCTCAACTTCATCACTGAGT
10 ACATCAAGGGCGGCACGCTCCGGGGCATCATC
AAGAGCATGGACAGCCAGTACCCATGGAGCCAGAGAGTGAGCTTTGC
CAAGGACATCGCATCAGGGATGGCCTACCTCCA

SEQUENCE LISTING
15 CTCCATGAACATCATCCACCGAGACCTCAACTCCCACAACTGCCTGGT
Sequence of LIM kinase 1
(SEQ ID NO. 1)
GCGCCGAGCCGGTTTCCCCGCCGGTGTCCGAGAGGCGCCCCCGGCCCG

CCGCGAGAACAAGAATGTGGTGGTGGCTGACT

GCCCGGCCCGGCCCGCGCCCTCCGCCCCCGCC

TCGGGCTGGCGCGTCTCATGGTGGACGAGAAGACTCAGCCTGAGGGC

TCCCCGGGCCGGCGGCGGTGGGCGAGCTCGCGGGCCCGGCCGCCCCC

20

CTGCGGAGCCTCAAGAAGCCAGACCGCAAGAAG

AGCCCCAGCCCCGCCGGGCCCCGCCCCCCGTCG

CGCTACACCGTGGTGGGCAACCCCTACTGGATGGCACCTGAGATGATC

AGTGCATGAGGTTGACGCTACTTTGTTGCACCTGGAGGGAAGAACGTA

AACGGCCGCAGCTATGATGAGAAGGTGGATGT

TGGGAGAGGAAGGAAGCGAGTTGCCCGTGTGT

25

GTTCTCCTTTGGGATCGTCCTGTGCGAGATCATCGGGCGGGTGAACGC

GCAAGCTGCGGCCAGAGGATCTATGATGGCCAGTACCTCCAGGCCCTG

AGACCCTGACTACCTGCCCCGCACCATGGACT

AACGCGGACTGGCACGCAGACTGCTTCAGGTG

TTGGCCTCAACGTGCGAGGATTCCTGGACCGCTACTGCCCCCCAAACT

TTGTGACTGCAGTGCCTCCCTGTCGCACCAGTACTATGAGAAGGATGG

GCCCCCCGAGCTTCTTCCCCATCACCGTGCGC

30
GCAGCTCTTCTGCAAGAAGGACTACTGGGCCC

TGTTGCGATCTGGACCCCGAGAAGAGGCCATCCTTTGTGAAGCTGGAA

GCTATGGCGAGTCCTGCCATGGGTGCTCTGAGCAAATCACCAAGGGAC

CACTGGCTGGAGACCCTCCGCATGCACCTGGC

TGGTTATGGTGGCTGGGGAGCTGAAGTACCAC
CCCGAGTGTTTCATCTGCCTCACGTGTGGGACCTTTATCGGTGACGGG

CGGCCACCTGCCACTGGGCCCACAGCTGGAGCAGCTGGACAGAGGTT
35

TCTGGGAGACCTACCGGCGCGGCGAGAGCGGAC

GACACCTACACGCTGGTGGAGCACTCCAAGCT

TGCCTGCCCACCCTGAGGTCCCCGACTGAGCCAGGGCCACTCAGCTGC

GTACTGCGGGCACTGCTACTACCAGACTGTGGTGACCCCCGTCATCGA
GCAGATCCTGCCTGACTCCCCTGGCTCCCACC

CCCTGTCCCCACCTCTGGAGAATCCACCCCCA
40

CCAGATTCCTCCGCGGGAGGTGGCCCTCAGCTGGGACAGTGGGGACC

TGCCCCACACCGTCACCCTGGTGTCCATCCCAGCCTCATCTCATGGCA

CAGGCTTCTCCTCAGAGCCAGGCCCTGACTTGC

AGCGTGGACTTTCAGTCTCCATTGACCCCCCG

CTTCTCCCACCCCGTGGACCGCTTCCCCTGCCTTCTCTCTGCCGTGGCC

CACGGCCCACCGGGCTGTGGCACCGAGCACTCACACACCGTCCGCGTC

45 CAGAGCCGGCCCAGCTGCACACACACACCAT

CAGGGAGTGGATCCGGGCTGCATGAGCCCAGA

GCTCTCGCCCTGCTGTAACCTCTGTCTTGGCAGGGCTGTCCCCTCTTGC

TGTGAAGAATTCCATCCACGTCGGAGACCGGATCTTGGAAATCAATGG

TTCTCCTTGCATGAGCTGGAGGGCCTGTGTG

CACGCCCATCCGAAATGTGCCCCTGGACGAGA

50 AGTTACGCCCCTTTCCACACGCCGCTGCCCCAGCAACCCTGTTCACGC

TTGACCTGCTGATTCAGGAAACCAGCCGCCTGCTCCAGCTGACCCTCG

TCCACCTGTCTGGTCCATAGCTCCCTGGAGGC

AGCATGACCCTCACGATACACTGGGCCACGGG

TGGGCCAGGAGGCAGCCTCCGAACCATGCCCCATATAACGCTTGGGTG

CTGGGGCCTGAGACCAGCCCCCTGAGCTCTCCGGCTTATACTCCCAGC
GGGGAGGCGGGCAGCTCTGCCCGGCAGAAACC
TGTCTTGAGGAGCTGCAGCATCGACAGGTCTCCGGGCGCTGGCTCACT
GGGCTCCCCGGCCTCCCAGCGCAAGGACCTGG
GTCGCTCTGAGTCCCTCCGCGTAGTCTGCCGGCCACACCGCATCTTCC

55 CGTGGGAGGGCGCACATCAGGGCAGAGGCCAA
GTTCCAGGTGTCTGTGTTCCCAGGAACCAAATGGGGAGTCTGGGGCCC
GTTTTCCCCCCAGGGGGTGTCTAGGTAGCAAC
60 AGGTATCGAGGACTCTCCAAACCCCCAAAGCAGAGAGAGGGCTGATC
CCATGGGGCGGAGGTCCCCAGTGGCTGAGCAAA

GGCCGTCGGACCTCATCCACGGGGAGGTGCTG
CAGCCCCTTCTCTCGCTTTGGGTCTTTTTTTTGTTTCTTTCTTAAAGCCA
GGCAAGGGCTGCTTCGGCCAGGCTATCAAGGTGACACACCGTGAGAC
65 CTTTAGTGAGAAGCAGGTACCAAGCCTCAG
AGGTGAGGTGATGGTGATGAAGGAGCTGATCCG
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SEQUENCE LISTING

SEQUENCE LISTING

GGTGAAGGGGGTCCCTTGAGGGAGCGTGGAGCTGCGGTGCCCTGGCC

TTTTATTTTTGTGGCGGGCGGGGGTGGGAGGG

GGCGATGGGGAGGAGCCGGCTCCGGCAGTGAGA

CCATTTTGTCACTTTGCCTCAGTTGAGCATCTAGGAAGTATTAAAACTG

GGATAGGCACAGTGGACCGGGCAGGTGTCCACCAGCAGCTCAGCCCC

TGAAGCTTTCTCAGTGCACTTTGAACCTGGA

TGCAGTCATCTCAGAGCCCCTTCCCGGGCCTCT

AAACAATCCCAACAGGCCCGTGGGACCATGACTTAGGGAGGTGGGAC
10

CCCCCAAGGCTCCCTGCCCCTCCTCATGCCCCTCTGTCCTCTGCGTTTT

CCACCCACCCCCATCCAGGAACCGTGACGTCCA

TTCTGTGTAATCTATTTTTTAAGAAGAGTTT

AGGAACCAAACCCAGACGCAGAACAATAAAATAAATTCCGTACTCCC

GTATTATTTTTTCATACGGCTGCAGCAGCAGCTGCCAGGGGCTTGGGA

CA CCC

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH, 3332
TYPE, DNA
ORGANISM, Homo sapiens

<400>

SEQUENCE, 1

3

gcgccgagcc ggtttccccg ccggtgtccg agaggcgccc ccggcccggc ccggcccggc

60

ccgcgccctc cgcccccgcc tccccgggcc ggcggcggtg ggcgagctcg cgggcccggc

120

cgcccccagc cccagccccg ccgggccccg ccccccgtcg agtgcatgag gttgacgcta

180

ctttgttgca cctggaggga agaacgtatg ggagaggaag gaagcgagtt gcccgtgtgt

240

gcaagctgcg gccagaggat ctatgatggc cagtacctcc aggccctgaa cgcggactgg

300

cacgcagact gcttcaggtg ttgtgactgc agtgcctccc tgtcgcacca gtactatgag

360

aaggatgggc agctcttctg caagaaggac tactgggccc gctatggcga gtcctgccat

420

gggtgctctg agcaaatcac caagggactg gttatggtgg ctggggagct gaagtaccac

480

cccgagtgtt tcatctgcct cacgtgtggg acctttatcg gtgacgggga cacctacacg

540

ctggtggagc actccaagct gtactgcggg cactgctact accagactgt ggtgaccccc

600

gtcatcgagc agatcctgcc tgactcccct ggctcccacc tgccccacac cgtcaccctg

660

gtgtccatcc cagcctcatc tcatggcaag cgtggacttt cagtctccat tgaccccccg

720

cacggcccac cgggctgtgg caccgagcac tcacacaccg tccgcgtcca gggagtggat

780

ccgggctgca tgagcccaga tgtgaagaat tccatccacg tcggagaccg gatcttggaa

840

atcaatggca cgcccatccg aaatgtgccc ctggacgaga ttgacctgct gattcaggaa

900

accagccgcc tgctccagct gaccctcgag catgaccctc acgatacact gggccacggg

960

ctggggcctg agaccagccc cctgagctct ccggcttata ctcccagcgg ggaggcgggc

1020

agctctgccc ggcagaaacc tgtcttgagg agctgcagca tcgacaggtc tccgggcgct

1080

ggctcactgg gctccccggc ctcccagcgc aaggacctgg gtcgctctga gtccctccgc

1140

gtagtctgcc ggccacaccg catcttccgg ccgtcggacc tcatccacgg ggaggtgctg

1200

ggcaagggct gcttcggcca ggctatcaag gtgacacacc gtgagacagg tgaggtgatg

1260

gtgatgaagg agctgatccg gttcgacgag gagacccaga ggacgttcct caaggaggtg

1320

aaggtcatgc gatgcctgga acaccccaac gtgctcaagt tcatcggggt gctctacaag

1380

gacaagaggc tcaacttcat cactgagtac atcaagggcg gcacgctccg gggcatcatc

1440
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aagagcatgg acagccagta cccatggagc cagagagtga gctttgccaa ggacatcgca

1500

tcagggatgg cctacctcca ctccatgaac atcatccacc gagacctcaa ctcccacaac

1560

tgcctggtcc gcgagaacaa gaatgtggtg gtggctgact tcgggctggc gcgtctcatg

1620

gtggacgaga agactcagcc tgagggcctg cggagcctca agaagccaga ccgcaagaag

1680

cgctacaccg tggtgggcaa cccctactgg atggcacctg agatgatcaa cggccgcagc

1740

tatgatgaga aggtggatgt gttctccttt gggatcgtcc tgtgcgagat catcgggcgg

1800

gtgaacgcag accctgacta cctgccccgc accatggact ttggcctcaa cgtgcgagga

1860

ttcctggacc gctactgccc cccaaactgc cccccgagct tcttccccat caccgtgcgc

1920

tgttgcgatc tggaccccga gaagaggcca tcctttgtga agctggaaca ctggctggag

1980

accctccgca tgcacctggc cggccacctg ccactgggcc cacagctgga gcagctggac

2040

agaggtttct gggagaccta ccggcgcggc gagagcggac tgcctgccca ccctgaggtc

2100

cccgactgag ccagggccac tcagctgccc ctgtccccac ctctggagaa tccaccccca

2160

ccagattcct ccgcgggagg tggccctcag ctgggacagt ggggacccag gcttctcctc

2220

agagccaggc cctgacttgc cttctcccac cccgtggacc gcttcccctg ccttctctct

2280

gccgtggccc agagccggcc cagctgcaca cacacaccat gctctcgccc tgctgtaacc

2340

tctgtcttgg cagggctgtc ccctcttgct tctccttgca tgagctggag ggcctgtgtg

2400

agttacgccc ctttccacac gccgctgccc cagcaaccct gttcacgctc cacctgtctg

2460

gtccatagct ccctggaggc tgggccagga ggcagcctcc gaaccatgcc ccatataacg

2520

cttgggtgcg tgggagggcg cacatcaggg cagaggccaa gttccaggtg tctgtgttcc

2580

caggaaccaa atggggagtc tggggcccgt tttcccccca gggggtgtct aggtagcaac

2640

aggtatcgag gactctccaa acccccaaag cagagagagg gctgatccca tggggcggag

2700

gtccccagtg gctgagcaaa cagccccttc tctcgctttg ggtctttttt ttgtttcttt

2760

cttaaagcca ctttagtgag aagcaggtac caagcctcag ggtgaagggg gtcccttgag

2820

ggagcgtgga gctgcggtgc cctggccggc gatggggagg agccggctcc ggcagtgaga

2880

ggataggcac agtggaccgg gcaggtgtcc accagcagct cagcccctgc agtcatctca

2940

gagccccttc ccgggcctct cccccaaggc tccctgcccc tcctcatgcc cctctgtcct

3000

ctgcgttttt tctgtgtaat ctatttttta agaagagttt gtattatttt ttcatacggc

3060

tgcagcagca gctgccaggg gcttgggatt ttatttttgt ggcgggcggg ggtgggaggg

3120

ccattttgtc actttgcctc agttgagcat ctaggaagta ttaaaactgt gaagctttct

3180

cagtgcactt tgaacctgga aaacaatccc aacaggcccg tgggaccatg acttagggag

3240

gtgggaccca cccaccccca tccaggaacc gtgacgtcca aggaaccaaa cccagacgca

3300

gaacaataaa ataaattccg tactccccac cc

3332

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 31
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 2
gacgacgaca agatggcctc cggtgtggct g

<210> SEQ ID NO 3

31
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<211>
<212>
<213>
<220>
<223>

LENGTH, 31
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 3
gaggagaagc ccggttcaca aaggcttgcc c

31

What is claimed is:

4. The method of claim 1, wherein said cancer cell metasta1. A method of treating a subject exhibiting a cancer cell 15 sis comprises breast cancer cells.
5. Themethodofclaiml, whereinsaidcancercellmetasta-

metastasis comprising administering to said subject a therapeutically effective dose of a composition comprising an
RNA interfering molecule or a ribozyme that targets SEQ ID
N0.1.
2. The method of claim 1, wherein said cancer cell metastasis comprises prostate cancer cells.
3. The method of claim 1, wherein said cancer cell metastasis comprises ovarian cancer cells.

20

sis comprises lung cancer cells.
6. The method of claim 1, wherein said administering is
transdermal, intravenous, intraperitoneal or implanted
administration.
7. The method of claim 1 wherein said subject is experiencing a recurrence of prostate cancer, and said administering
comprises reducing the proliferation of prostate cancer cells.

* * * * *

